The Company Methodology GlaxoSmithKline Slovakia s.r.o. for the disclosure of value transfers to healthcare professionals and health organizations under the AIFP /Association of Innovative Pharmaceutical Industry/ Code of Ethics (in accordance with EFPIA Disclosure Code).

- All direct and indirect transfers of values whose receiver is a healthcare professional or health organization are subject to disclosure.
- The value transfers that are subject to the disclosure under the Act no. No 362/2011 on medicinal products and medical devices, and which were for the year 2020 reported at [http://www.nczisk.sk/Statisticke-zistovania/Vydavky_podla_zakona_o_liekoch/Pages/default.aspx](http://www.nczisk.sk/Statisticke-zistovania/Vydavky_podla_zakona_o_liekoch/Pages/default.aspx) are not included in this report.
- The submitted report contains only those value transfers for the year 2020 (1.1.2020 - 31.12.2020) which, according to the differences in the EFPIA definition and local legislation, were not disclosed; the date of payment in case of pecuniary interest, and the date of execution for benefit in kind are decisive for the inclusion in the period.
- Money transfers are disclosed as net payments exclusive of tax / gross payments including tax.
- Non-monetary transfer values are disclosed in the form of total amount, including VAT.

**Definitions**

- **“Healthcare professional (HP)”** means any natural person who is a member of healthcare, dental, pharmaceutical or nursing profession, or other person who may prescribe, buy, provide, recommend or administer a medicinal product within her/his professional activity, and whose main practice, principal place of business or her/his place of residence is in the Slovak Republic. To avoid any doubts, the definition of healthcare professional includes also: any official or employee of government agency or other organization (whether in the public or private sector) who may prescribe, buy, provide or administer medicines, and any employee whose main activity is the performance of healthcare professional occupation, but excluding the large-scale distributors of medicinal products.

- **“Health organization (HO)”** means any legal entity that is an association or organization providing healthcare, a health or research association or organization (irrespective of legal or organizational form) such as a hospital, clinic, foundation, university or other educational institution or educational association (e.g. Slovak Medical Association) whose registered office, place of incorporation or principal place of business is in the Slovak Republic, or through which services are provided by one or more healthcare professionals.
**Individual categories of transfers disclosed**

- Transfers of values to **health organizations**
  - **Subsidies and grants**
    Gifts and grants for health organizations to support health care, including gifts and grants (funds or material benefits) to institutions, organizations or associations consisting of healthcare professionals and / or which provide health care.
  - **Contributions to the costs of events**
    Contributions to the costs related to a professional event performed by a health organization or third parties, including sponsorship of healthcare professionals for the purpose of attending professional events:
    i. registration fees;
    ii. sponsorship agreements with health organizations or third parties that health organizations have entrusted with organizing a professional event and
    iii. travel expenses and accommodation expenses
    iv. purchase of services during the event, such as rental of exhibition premises, purchase of advertising space, advertising in the event material, etc., is also considered a contribution to the costs of the event
  - **Fees for services and consultations**
    The transfers of value arising from or relating to contracts between the company and institutions, organizations or associations of health professionals based on which such institutions, organizations or associations provide the company with any type of service, or any other type of financing not included in the previous categories. Remuneration and value transfers relating to the costs agreed in the written agreement relating to the agreed activity will be disclosed as two separate amounts (payment for a service + paid costs related to the provision of service).

- Transfers of values to **healthcare professional**
  - **Contributions to the costs of events**
    Contributions to the costs related to a professional event:
    i. registration fees; and
    ii. travel expenses and accommodation expenses
  - **Fees for services and consultations**
    The value transfers arising from or related to contracts between the company and healthcare professionals based on which healthcare professionals provide members with any type of service, or any other type of funding not included in the previous categories. Remuneration and value transfers related to the costs agreed in the written agreement relating to the agreed activity will be disclosed as two separate amounts (payment for the service + paid costs related to the provision of service if incurred; e.g. the payment for a vocational training / lecture + payment of travel expenses to the place of training).
Aggregate disclosure

The transfer of value, where it is not possible to disclose certain information individually for legitimate reasons (e.g. an ungiven consent to the disclosure of personal data), is disclosed by the Company for the reporting period as the aggregate amount per such value transfers. Such aggregate disclosure identifies for each category the number of recipients listed in such disclosure, in absolute numbers and as a percentage out of all recipients, and the aggregate amount per the value transfers to such recipients.

Transfers of value in research and development

For the period in question, the company discloses in cumulative terms the transfers of value related to research and development as one amount. Costs that are disclosed pursuant to the Act no. No 362/2011 on medicinal products and medical devices are not part of this report.

Tesaro

Tesaro TOVs – Following the acquisition of Tesaro in 2020, GSK have aligned with the EFPIA Board resolution made in 2016 that in the case of a new entity (following M&A) the implementation of the EFPIA Disclosure associated with the acquisition can be implemented with a 12-month delay. Therefore, all TOVs incurred for Tesaro activity in GlaxoSmithKline Slovakia s.r.o. in 2020 will be disclosed by Tesaro.

Missing Data – data from Event Management Agencies are not yet available due to delays caused by COVID 19.

Missing data – At the time of publishing GSK GlaxoSmithKline Slovakia s.r.o. was not able to collect all TOV data collected on behalf of GSK from some 3rd party agencies due to processing delays caused by COVID 19. GlaxoSmithKline Slovakia s.r.o. will add the missing data to this report as soon as the 3rd party data becomes available later in the year and publish an amendment where required.